

Consent Screening Questions for 2022-2023: Quadrivalent Inactivated Influenza Vaccine - Standard Dose (QIIV-SD) Quadrivalent Inactivated High Dose Influenza (IIV4HD) Pneumococcal Polysaccharide Vaccine (Pneu-P-23)

Ensure the client or legal guardian has had an opportunity to review the vaccine fact sheets.

		Immunize	Precaution or DO NOT Immunize
1.	Are you feeling well today?	No concerns	Do NOT immunize: Severe acute illness with or without fever
2.	Do you have any allergies?	Allergy to eggs, egg products, or chicken proteins- NACI has concluded that egg allergic individuals without other contraindications may be vaccinated against influenza (with any product) without a prior influenza vaccine skin test and with the full dose. The vaccine may be given in any settings where vaccines are routinely administered.	Documented severe allergy to a component of the vaccine(s): Withhold the vaccine product that contains that component if there is a known or suspected severe allergy. Use an alternate product that does not contain that component, if available If no alternate product available refer client to primary care provider for further assessment
3.	Do you have any health conditions that require regular visits to the doctor?	None	Bleeding disorders: Persons with a bleeding disorder should consult with their health care provider prior to immunization.
4.	Are you taking any medications?	None	Immunosuppressants: The vaccine may be less effective in individuals receiving medications which cause immunosuppression, or who are immunosuppressed from a medical condition. Individuals on chemotherapy may wish to seek advice from their physician on the best timing to receive the influenza/pneumococcal vaccines.
5.	Have you ever had a serious reaction following an immunization?	Oculorespiratory Syndrome (ORS) ORS <u>without</u> lower respiratory tract symptoms	 Previous allergic or anaphylactic type of reaction following influenza or pneumococcal vaccines- Consult with identified medical specialist as needed. Guillain-Barré Syndrome (GBS) If client developed GBS within 6 weeks of a previous influenza vaccine Oculorespiratory Syndrome (ORS) ORS with lower respiratory tract symptoms- Should have an expert review.

Winnipeg Regional Office régional de la Health Authority santé de Winnipeg Caring for Health À l'écoute de notre so

Consent Screening Questions for 2022-2023: Quadrivalent Inactivated Influenza Vaccine - Standard Dose (QIIV-SD) Quadrivalent Inactivated High Dose Influenza (IIV4HD) Pneumococcal Polysaccharide Vaccine (Pneu-P-23)

	Caring for Health — A l'écouté de notre santé	Flieumococcai Folysacchiande Vacchie (Flieu-F-23)		
6	6. Are you pregnant or possibly	NACI recommends the inclusion of all pregnant women, at	Do Not Immunize:	
	pregnant?	any stage of pregnancy, among the specifically recommended recipients of inactivated influenza vaccine. Quadrivalent Inactivated Influenza Vaccine - Standard Dose (QIIV-SD)	Quadrivalent Inactivated High Dose Influenza (IIV4HD) is only applicable to those 65 years of age and older.	
		For pneumococcal vaccine: If indicated, pregnant women can be vaccinated with Pneu-P-23 vaccine, as there is no evidence to suggest a risk to the fetus or to the pregnancy from immunization with pneumococcal vaccines. Women who are breastfeeding can be vaccinated with pneumococcal vaccines		

Pneumococcal Vaccine

Check for eligibility:

- Ensure pneumococcal database or PHIMS (if available) at clinic has been checked, and client does not recall any recent vaccines in the past 2 months.
- If they have received a recent immunization, and there is only access to the pneumococcal database, call the local public health office to check PHIMS directly. Also consider that there may be a delay in recording of immunization records submitted from physician claims into PHIMS.
- If previously immunized do NOT immunize. If they have a high risk condition, refer to their primary care provider for further recommendations for additional immunizations.
- Routine re-immunization with pneumococcal polysaccharide vaccine is **not** recommended. However, re-immunization should be considered for those at highest risk of invasive infection. If a booster dose of Pneu-P-23 vaccine is recommended, it should be administered at least 5 years after any previous dose of Pneu-P-23 vaccine (Canadian Immunization Guide). Clients who may be eligible for re-immunization should be referred to their primary care provider to determine if they should be re-immunized.

Note: There is no deferral period for those who receive influenza or pneumococcal vaccines to donate blood. (as per Canadian Blood Services https://www.blood.ca/en/blood/am-i-eligible-donate-blood/abcs-eligibility

Sources:

NACI statement on Seasonal Influenza vaccine 2022-2023

Pneumococcal Vaccine, Canadian Immunization Guide